Shenzhen New Industries Biomedical Engineering (300832) Q2 2024 earnings summary

Executive summary

• Achieved revenue of ¥2.21 billion, up 18.54% year-over-year, with net profit attributable to shareholders of ¥903 million, up 20.42%.

• Domestic and overseas business both saw double-digit growth, with overseas revenue up 22.79% and domestic up 16.30%.

• Gross margin improved to 72.78%, up 1.29 percentage points year-over-year.

• Continued expansion in high-end medical terminals and international markets, with new product launches and R&D advancements.

• No interim dividend, bonus shares, or capital increase from reserves planned for the half-year.

Financial highlights

• Operating income: ¥2,210,936,110.91, up 18.54% year-over-year.

• Net profit attributable to shareholders: ¥903,149,037.81, up 20.42% year-over-year.

• Basic and diluted EPS: ¥1.1495, up 20.40% year-over-year.

• Operating cash flow: ¥618,461,493.76, up 17.46% year-over-year.

• Total assets: ¥8,342,882,096.79, up 1.46% from year-end.

Outlook and guidance

• Company expects continued growth in both domestic and international markets, driven by product innovation and market expansion.

• Focus on high-throughput instruments and comprehensive laboratory solutions to capture large medical terminal clients.

• Ongoing R&D and new product launches to support future growth.